Table 2.
The association between co-expression of SALL4/ALDH1A1 and clinicopathological parameters of serous ovarian carcinoma (SOC) samples (Intensity of staining and H-score) (P value; Pearson’s χ2 test)
| Patients and tumor characteristics | Total samples N (%) |
SALL4/ALDH1 phenotypes | P-value | |||
|---|---|---|---|---|---|---|
| SALL4 Low /ALDH1A1 Low | SALL4 Low /ALDH1A1 High | SALL4 High /ALDH1A1 Low | SALL4 High /ALDH1A1 High | |||
| OSC | 45 (100.0) | 19 (42.2) | 14 (31.1) | 6 (13.3) | 6 (13.3) | |
| Mean age, years (Range) | 45 (16-74) | |||||
| ≤Mean age | 19 (42.2) | 7 (36.8) | 5 (35.7) | 2 (33.3) | 5 (83.3) | 0.185 |
| >Mean age | 26 (57.8) | 12 (63.2) | 9 (64.3) | 4 (66.7) | 1 (16.7) | |
| Mean tumor size (cm) | 8.28 | |||||
| ≤Mean | 25 (55.6) | 11 (78.6) | 9 (75.0) | 3 (75.0) | 2 (33.3) | 0.215 |
| >Mean | 11 (24.4) | 3 (21.4) | 3 (25.0) | 1 (25.0) | 4 (66.7) | |
| Not identified | 9 (20.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Histological grade | ||||||
| I | 20 (44.4) | 9 (47.4) | 7 (50.0) | 0 (0.0) | 4 (66.7) | 0.359 |
| II | 4 (8.9) | 2 (10.5) | 1 (7.1) | 1 (16.7) | 0 (0.0) | |
| III | 21 (46.7) | 8 (42.1) | 6 (42.9) | 5 (83.3) | 2 (33.3) | |
| IV | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| FIGO stage | ||||||
| I | 10 (22.2) | 5 (26.3) | 3 (21.4) | 0 (0.0) | 2 (33.3) | 0.047 |
| II | 15 (33.3) | 5 (26.3) | 7 (50.0) | 0 (0.0) | 3 (50.0) | |
| III | 20 (44.4) | 9 (47.4) | 4 (28.6) | 6 (100.0) | 1 (16.7) | |
| IV | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Lymph node (LN) metastasis | ||||||
| Involved | 20 (44.4) | 9 (50.0) | 6 (50.0) | 2 (33.3) | 3 (50.0) | 0.903 |
| None | 22 (48.9) | 9 (50.0) | 6 (50.0) | 4 (66.7) | 3 (50.0) | |
| Not identified | 3 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Vascular invasion (VI) | ||||||
| Involved | 5 (11.1) | 1 (5.6) | 1 (8.3) | 2 (33.3) | 1 (16.7) | 0.309 |
| None | 37 (82.2) | 17 (94.4) | 11(91.7) | 4 (66.7) | 5 (83.3) | |
| Not identified | 3 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Omentum | ||||||
| Involved | 9 (20.0) | 5 (27.8) | 1 (8.3) | 2 (33.3) | 1 (16.7) | 0.524 |
| None | 33 (73.3) | 13 (72.2) | 11 (91.7) | 4 (66.7) | 5 (83.3) | |
| Not identified | 3 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Fallopian tube | ||||||
| Involved | 9 (20.0) | 4 (22.2) | 3 (25.0) | 2 (33.3) | 0 (0.0) | 0.524 |
| None | 33 (73.3) | 14 (77.8) | 9 (75.0) | 4 (66.7) | 6 (100.0) | |
| Not identified | 3 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Cervix | ||||||
| Involved | 8 (17.8) | 5 (27.8) | 1 (8.3) | 2 (33.3) | 0 (0.0) | 0.263 |
| None | 34 (75.6) | 13 (72.2) | 11 (91.7) | 4 (66.7) | 6 (100.0) | |
| Not identified | 3 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Endometrium | ||||||
| Involved | 5 (11.1) | 3 (16.7) | 1 (8.3) | 1 (16.7) | 0 (0.0) | 0.688 |
| None | 37 (82.2) | 15 (83.3) | 11 (91.7) | 5 (83.3) | 6 (100.0) | |
| Not identified | 3 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Myometrium | ||||||
| Involved | 6 (13.3) | 3 (16.7) | 1 (8.3) | 1 (16.7) | 1 (16.7) | 0.922 |
| None | 36 (80.0) | 15 (83.3) | 11 (91.7) | 5 (83.3) | 5 (83.3) | |
| Not identified | 3 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Vagina | ||||||
| Involved | 10 (22.2) | 3 (16.7) | 3 (25.0) | 3 (50.0) | 1 (16.7) | 0.399 |
| None | 32 (71.1) | 15 (83.3) | 9 (75.0) | 3 (50.0) | 5 (83.3) | |
| Not identified | 3 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Peritoneum | ||||||
| Involved | 3 (6.7) | 2 (10.5) | 1 (8.3) | 0 (0.0) | 0 (0.0) | 0.728 |
| None | 40 (88.9) | 17 (89.5) | 11 (91.7) | 6 (100.0) | 6 (100.0) | |
| Not identified | 2 (4.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Lymphovascular space invasion | ||||||
| Involved | 8 (17.8) | 4 (21.1) | 3 (25.0) | 1 (16.7) | 0 (0.0) | 0.618 |
| None | 35 (77.8) | 15 (78.9) | 9 (75.0) | 5 (83.3) | 6 (100.0) | |
| Not identified | 2 (4.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Perineural invasion | ||||||
| Present | 3 (6.7) | 0 (0.0) | 2 (16.7) | 1 (16.7) | 0 (0.0) | 0.230 |
| Absent | 39 (86.7) | 18 (100.0) | 10 (83.3) | 5 (83.3) | 6 (100.0) | |
| Not identified | 3 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Colon | ||||||
| Involved | 10 (22.2) | 4 (22.2) | 3 (23.1) | 3 (50.0) | 0 (0.0) | 0.237 |
| None | 33 (73.3) | 14 (77.8) | 10 (76.9) | 3 (50.0) | 6 (100.0) | |
| Not identified | 2 (4.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Small intestine | ||||||
| Involved | 4 (8.9) | 3 (16.7) | 1 (8.3) | 0 (0.0) | 0 (0.0) | 0.503 |
| None | 38 (84.4) | 15 (83.3) | 11 (91.7) | 6 (100.0) | 6 (100.0) | |
| Not identified | 3 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Post-cul-de-sac | ||||||
| Involved | 7 (15.6) | 5 (27.8) | 0 (0.0) | 2 (33.3) | 0 (0.0) | 0.094 |
| None | 35 (77.8) | 13 (72.2) | 12 (100.0) | 4 (66.7) | 6 (100.0) | |
| Not identified | 3 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Paracolic lymph node | ||||||
| Involved | 5 (11.1) | 4 (22.2) | 1 (8.3) | 0 (0.0) | 0 (0.0) | 0.309 |
| None | 37 (82.2) | 14 (77.8) | 11 (91.7) | 6 (100.0) | 6 (100.0) | |
| Not identified | 3 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Distant metastasis | ||||||
| Present | 20 (44.4) | 6 (31.6) | 6 (42.9) | 6 (100.0) | 2 (33.3) | 0.028 |
| Absent | 25 (55.6) | 13 (68.4) | 8 (57.1) | 0 (0.0) | 4 (66.7) | |
| Tumor recurrence | ||||||
| Yes | 25 (55.6) | 10 (52.6) | 6 (42.9) | 6 (100.0) | 3 (50.0) | 0.119 |
| No | 20 (44.4) | 9 (47.4) | 8 (57.1) | 0 (0.0) | 3 (50.0) | |